Guidelines & Consensus
Improving Patient Communication in Advanced Oncology
Gehl et alActa Oncologica
Rapid advancements in oncology have led to increasingly sophisticated diagnostic and therapeutic modalities. However, the intrinsic complexity of these high-tech interventions, paired with the absence of standardized, accessible communication pathways, creates substantial barriers for patients seeking reliable medical information, ultimately exacerbating disparities in cancer care.
Under the framework of Europe's Beating Cancer Plan, the Joint Action Network of Expertise on Cancer (JANE-2) evaluated these communication challenges through its High-Tech Medical Resources work package. Domain leaders collaborated with patient representatives to examine technological complexities and structural information deficits across seven critical therapeutic and diagnostic areas: Nuclear Medicine, Radiomics, Innovative Radiotherapy, Innovative Surgery, Physical Methods of Ablation, Cell Therapies, and Ex-vivo Testing of Agents.
To address these disparities and improve health literacy surrounding complex interventions, the initiative formulated targeted solutions and developed specialized patient information tools corresponding to each of the seven high-tech domains, made available as supplementary clinical resources. These tools aim to clarify novel treatment mechanisms, support shared decision-making, and promote equitable access to innovative cancer care.
Key Takeaways
- The Joint Action Network of Expertise on Cancer (JANE-2) established dedicated patient information tools spanning seven rapidly evolving oncology domains: Nuclear Medicine, Radiomics, Innovative Radiotherapy, Innovative Surgery, Physical Methods of Ablation, Cell Therapies, and Ex-vivo Testing of Agents.
- A lack of clear, structured communication pathways and the inherent complexity of advanced oncology technologies directly drive healthcare inequalities by impeding patient understanding of novel diagnostic and therapeutic options.
Read the original sourceActa Oncologica
